Avendus Invests Rs. 300 Cr in Aragen Life Sciences CRDMO

Avendus Future Leaders Fund (FLF) has announced a Rs. 300 crore (US$34.2 million) investment in Aragen Life Sciences, a leading Indian contract research, development, and manufacturing organization (CRDMO), with co-investment from SBI Life Insurance.

The funding, executed through Avendus Future Leaders Fund III, involves acquiring a minority stake in Aragen and marks the fund’s second investment after its stake in La Renon Healthcare. Founded in 2001, Aragen provides integrated research and manufacturing solutions for pharmaceuticals, spanning small molecules and biologics. The company serves global pharmaceutical and biotech clients, supporting drug discovery, development, and manufacturing needs.

Key Highlights

• Avendus FLF III invests Rs. 300 crore in Aragen with SBI Life Insurance
• Aragen offers pharma R&D and manufacturing for small molecules & biologics
• Second FLF III investment, following La Renon Healthcare stake

Avendus Future Leaders Fund currently manages assets exceeding Rs. 3,750 crore (US$428 million), targeting late-stage companies with strong growth potential across sectors. This latest deal further expands the fund’s presence in the healthcare and life sciences domain.

Aragen’s board already includes marquee investors such as Goldman Sachs and Quadria Capital, underscoring its credibility in the global CRDMO market. The company is expected to leverage this funding to expand capacity, enhance R&D capabilities, and strengthen its position as a partner of choice for global pharma and biotech firms.

Also Read: GC Biopharma Taps Korber for Fast-Track MES Deployment in Korea

Earlier in May 2025, Avendus demonstrated active portfolio management with its successful exit from Juspay Technologies. This latest transaction reflects the fund’s continued focus on identifying high-growth companies and driving value creation for investors.